Incyte Reports Positive 24-Week Data for Povorcitinib in Hidradenitis Suppurativa
WILMINGTON, DE — Incyte (Nasdaq: INCY) released new 24-week interim data from its pivotal Phase 3 STOP-HS trials, showing that its oral JAK1 inhibitor povorcitinib (INCB54707) delivered sustained efficacy and …
Incyte Reports Positive 24-Week Data for Povorcitinib in Hidradenitis Suppurativa Read More